Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NEU1 | Q99519 | 4/20 | 0.40 |
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22467337 | 1.00 | KDM4E (0.46) | KDM4EASAH1FAAHMEN1KMT2A | |
| SCHEMBL18645915 | 0.97 | ASAH1 (0.43) | KDM4EASAH1FAAHMEN1KMT2A | |
| SCHEMBL18992757 | 0.95 | FAAH (0.50) | KDM4EASAH1FAAHMEN1KMT2A | |
| SCHEMBL28446577 | 0.95 | FAAH (0.50) | KDM4EASAH1FAAHMEN1KMT2A | |
| SCHEMBL788541 | 0.93 | FAAH (0.53) | ASAH1FAAHMEN1KMT2ANAAA | |
| SCHEMBL22575879 | 0.93 | FAAH (0.53) | ASAH1FAAHMEN1KMT2ANAAA | |
| SCHEMBL31472777 | 0.93 | FAAH (0.53) | ASAH1FAAHMEN1KMT2ANAAA | |
| SCHEMBL12359197 | 0.93 | FAAH (0.53) | ASAH1FAAHMEN1KMT2ANAAA | |
| SCHEMBL31472778 | 0.93 | FAAH (0.53) | ASAH1FAAHMEN1KMT2ANAAA | |
| SCHEMBL28417284 | 0.93 | FAAH (0.53) | ASAH1FAAHMEN1KMT2ANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236055-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2022-02-01 | — | — | US | disclosed |
| CN-107428665-B | Method for producing (meth) acrylic ester | 东亚合成株式会社 | 2021-10-15 | — | — | CN | disclosed |
| CN-107406363-B | Method for producing (meth) acrylic ester | 东亚合成株式会社 | 2021-10-08 | — | — | CN | disclosed |
| CN-107709377-B | Curable composition | 东亚合成株式会社 | 2021-04-20 | — | — | CN | disclosed |
| CN-107709376-B | Curable composition | 东亚合成株式会社 | 2020-10-30 | — | — | CN | disclosed |
| US-20200308122-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2020-10-01 | — | — | US | disclosed |
| CN-107922555-B | Curable composition | 东亚合成株式会社 | 2020-08-28 | — | — | CN | disclosed |
| EP-2794576-A1 | NON-SYSTEMIC TGR5 AGONISTS | Ardelyx, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096771-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308122-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, SSTR5, FFAR3 | KDM4E 3217/4885ASAH1 123/4885FAAH 339/4885 |
| US-11236055-B2 | Non-systemic TGR5 agonists | SSTR5, GPR119, FFAR3 | KDM4E 2906/4885ASAH1 95/4885FAAH 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.